The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches
The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches, Published online: 04 February 2019; doi:10.1038/s41571-019-0169-5The development of more-targeted cancer therapies has not been matched by more-targeted imaging methods. This discrepancy has, in some scenarios, resulted in inaccurate assessments of the effects of novel therapies. In this Review, the authors describe potential novel imaging approaches that could be adopted to enable improvements in imaging-based monitoring of treatment responses and resistance. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 4, 2019 Category: Cancer & Oncology Authors: Mirjam Gerwing Ken Herrmann Anne Helfen Christoph Schliemann Wolfgang E. Berdel Michel Eisenbl ätter Moritz Wildgruber Source Type: research
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC, Published online: 04 February 2019; doi:10.1038/s41571-019-0173-9The advent of effective molecularly targeted treatments and immunotherapies for non-small-cell lung cancer (NSCLC) has greatly improved patient outcomes. Whereas most patients selected for treatment with molecularly targeted drugs derive benefits from these agents, benefit from immunotherapy is more difficult to predict. Herein, Camidge and colleagues compare and contrast predictive biomarkers for immunotherapy and targeted therapy of NSCLC to highlight considerat...
Source: Nature Clinical Practice Oncology - February 4, 2019 Category: Cancer & Oncology Authors: D. Ross Camidge Robert C. Doebele Keith M. Kerr Source Type: research
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy, Published online: 31 January 2019; doi:10.1038/s41571-019-0175-7Regulatory T (Treg) cells are implicated in cancer immune evasion and escape and thus contribute to tumour development and progression. In this Review, the authors provide an overview of the phenotypes and roles of Treg cells in the context of cancer and outline potential strategies to target this cell type in anticancer immunotherapy. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2019 Category: Cancer & Oncology Authors: Yosuke Togashi Kohei Shitara Hiroyoshi Nishikawa Source Type: research
Real-world data: towards achieving the achievable in cancer care
Real-world data: towards achieving the achievable in cancer care, Published online: 30 January 2019; doi:10.1038/s41571-019-0167-7In the past few years, the use of data from the real world has garnered increasing interest; however, studies using real-world data (RWD) should not be used as substitutes for clinical trials. The authors of this Review explore the quality of RWD, provide a framework for the use of RWD and draw attention to the methodological pitfalls inherent to using RWD. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 30, 2019 Category: Cancer & Oncology Authors: Christopher M. Booth Safiya Karim William J. Mackillop Source Type: research
Hybrid minimally invasive surgery overtakes open surgery
Hybrid minimally invasive surgery overtakes open surgery, Published online: 28 January 2019; doi:10.1038/s41571-019-0176-6Hybrid minimally invasive surgery overtakes open surgery (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 28, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Rectal cancer — not a waiting game?
Rectal cancer — not a waiting game?, Published online: 23 January 2019; doi:10.1038/s41571-019-0174-8Rectal cancer — not a waiting game? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research
Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review
Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review, Published online: 22 January 2019; doi:10.1038/s41571-019-0170-zIn 2018, the FDA approved 19 new drug and biologic applications, 38 supplemental drug and biologic applications and 4 biosimilar applications in oncology. These advances in anticancer therapy included a landmark approval of the first histology-agnostic, biomarker-defined new molecular entity and approvals based on real-time data review and novel end points, such as minimal residual disease rate and metastasis-free survival. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 22, 2019 Category: Cancer & Oncology Authors: Gideon M. Blumenthal Richard Pazdur Source Type: research
Desmoid tumours stalled by sorafenib
Desmoid tumours stalled by sorafenib, Published online: 21 January 2019; doi:10.1038/s41571-019-0172-xDesmoid tumours stalled by sorafenib (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 21, 2019 Category: Cancer & Oncology Authors: Katharine H. Wrighton Source Type: research
CRISPR–Cas: a tool for cancer research and therapeutics
CRISPR–Cas: a tool for cancer research and therapeutics, Published online: 21 January 2019; doi:10.1038/s41571-019-0166-8CRISPR systems have enabled important advances in cancer research by accelerating the development of study models or as a tool in genetic screening studies to discover and validate therapeutic targets. The authors of this Review discuss these applications and new potential uses, such as cancer detection and development of anticancer therapies. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 21, 2019 Category: Cancer & Oncology Authors: Hao Yin Wen Xue Daniel G. Anderson Source Type: research
FOLFIRINOX goes adjuvant
FOLFIRINOX goes adjuvant, Published online: 18 January 2019; doi:10.1038/s41571-019-0171-yFOLFIRINOX goes adjuvant (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 18, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Towards risk-stratified induction regimens
Towards risk-stratified induction regimens, Published online: 15 January 2019; doi:10.1038/s41571-019-0168-6Towards risk-stratified induction regimens (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 15, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research
Truly personalized therapy — an end to the era of one size fits all
Truly personalized therapy — an end to the era of one size fits all, Published online: 15 January 2019; doi:10.1038/s41571-018-0165-1In 2018, several trials in breast cancer have shown efficacy of strategies that rely on novel markers, including gene expression assays or pathological complete response. The relevance of targeted strategies in patient subgroups and of immunotherapy efficacy were demonstrated. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 15, 2019 Category: Cancer & Oncology Authors: Nadia Harbeck Rachel Wuerstlein Source Type: research
Reshaping the critical role of surgeons in oncology research
Reshaping the critical role of surgeons in oncology research, Published online: 07 January 2019; doi:10.1038/s41571-018-0149-1Historically, academic surgeons, so-called surgeon scientists, have been at the forefront of cancer research. However, the role of the surgeon scientist is changing, and concerns have been raised about declines in the number of surgeons performing basic science research alongside clinical activity. Herein, the multifactorial drivers of these changes are discussed and strategies to increase surgical engagement in oncology research are described. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 7, 2019 Category: Cancer & Oncology Authors: Robert. P. Jones Chandrakanth Are Thomas J. Hugh Dirk J. Gr ünhagen Jianmin Xu Charles M. Balch Graeme J. Poston Source Type: research
T-DM1 protects against invasive disease
T-DM1 protects against invasive disease, Published online: 03 January 2019; doi:10.1038/s41571-018-0164-2T-DM1 protects against invasive disease (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 3, 2019 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
ECHELON-2 — brentuximab raises PTCL outcomes to new levels
ECHELON-2 — brentuximab raises PTCL outcomes to new levels, Published online: 02 January 2019; doi:10.1038/s41571-018-0163-3ECHELON-2 — brentuximab raises PTCL outcomes to new levels (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 2, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research
